Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Lymphoma × sapanisertib × Clear all

Phase

Phase 2 2 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 2 Thyroid Neoplasms 1 Thyroid Carcinoma, Anaplastic 1 Lymphoma 1 Lung Neoplasms 1 Liver Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Merkel Cell 1

Interventions

Cyclophosphamide 43 Rituximab 42 fludarabine 22 Filgrastim 21 fludarabine phosphate 17 Lenalidomide 16 Radiotherapy 15 Prednisone 15 Peripheral Blood Stem Cell Transplantation 14 Etoposide 14 Melphalan 13 Busulfan 13 Vincristine 12 Doxorubicin 12 Tacrolimus 11 pembrolizumab 10 Methotrexate 10 Gemcitabine 9 obinutuzumab 8 Alemtuzumab 8 ibrutinib 7 Mycophenolic Acid 7 Granulocyte Colony-Stimulating Factor 7 Bendamustine Hydrochloride 7 Azacitidine 7 venetoclax 6 Whole-Body Irradiation 6 Vorinostat 6 Ifosfamide 6 Cytarabine 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02727777 2020-03-12

Phase II Study of TAK228 in Relapsed Lymphoma

M.D. Anderson Cancer Center

Phase 1/2 Terminated

4 enrolled 9 charts

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡